VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2021 | Waldenström’s therapy: what’s on the horizon?

The future of Waldenström’s macroglobulinemia therapy is bright, with various novel combinations currently under investigation. In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, delineates what’s on the therapeutic landscape for Waldenström’s. Specifically discussed is the combinatorial use of ibrutinib to achieve deeper responses. For example, ibrutinib is currently being trialed in combination with chemoimmunotherapy, proteasome inhibitors, the CXCR4 inhibitor, EPI-X 4, daratumumab and venetoclax. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

Disclosures

Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter